0
ARTICLE |

Biotechnology's Bequest: New Drugs, Diagnostics

Beverly Merz
JAMA. 1987;258(11):1435. doi:10.1001/jama.1987.03400110015005.
Text Size: A A A
Published online

ABSTRACT

BIOTECHNOLOGY seems to defy easy definition. At least Joan Bennett, PhD, who chaired the recent Second Annual Conference on Biotechnology sponsored by the American Society for Microbiology in San Diego, thinks so.

Bennett, who is professor of biology at Tulane University, New Orleans, opened the conference by explaining how she had gleaned the writings of lexicographers and semanticists, hoping to find a well-turned phrase that captures the essence of the new discipline. She said that she had come away dissatisfied, and is still working on an economical description that links the diverse enterprises crowded under the umbrella of biotechnology.

Bennett's conundrum became easy to understand during the ensuing three days. Presentations on new agents ran the gamut from anti-idiotype antibodies to xerophobic bacteria and new applications ranged from agricultural to zoological. The presenters appeared to share only one characteristic—a propensity for tinkering with the innards of some type of microbe.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs